By Girish Malhotra Patents are filed to preserve intellectual property for the duration of the patent life. This is the fundamental right of every inventor as they protect their invention from competitors and gives them competitive advantage. Pharmaceuticals have relied on this right to preserve their inventions. These patents are a treasure trove for the […]
Corporate IP Strategy – a High-Level View
October 18, 2012 by Leave a Comment
By Ian Maxwell There are two good strategic reasons why any operating company should have patents, and they both relate to financial return on investment: 1. To use a monopoly, suggested or realized by patents, to get a higher margin and/or higher revenues for products or services, and 2. For the value of the patents […]
How to build a world-class licensing programme
October 17, 2012 by Leave a Comment
By Mac Leckrone New business models and a growing anti-patent trend are changing the business of licensing. The challenge for licensing programme managers in this evolving landscape is to find ways of delivering greater value to customers. At least two ‘megatrends’ – large-scale shifts in the landscape – have the potential to change most of […]
IP Strategy for Drug Discovery: A Dedicated Research Firm’s Perspective
October 16, 2012 by Leave a Comment
By Vinita Radhakrishnan Given the nature of business of a dedicated research firm (DRF) in the pharmaceutical sector, intellectual property (IP), particularly, patents are considered to be the most valued asset. More times than not, the standing of a dedicated research firm, in the market place, is judged by the strength and nature of their […]
Patent strategy 101 – Keep it secret
October 15, 2012 by 1 Comment
By Pallavi Kharkar Do you have an invention ready in hand but are not able to file a patent? How will you protect it from being disclosed if you intend to eventually file a patent? Often disclosure is essential with partners, collaborators, investors, while developing advanced technologies with the help of external agencies and so […]
The Glassybaby Syndrome or Why Every Company is an IP Company
October 12, 2012 by Leave a Comment
By Louis Carbonneau Ever heard of Glassybaby? According to a recent Seattle Times article, “[Glassybaby] is a compelling small-business success story: After a seven-year battle with lung cancer, young mother develops colorful and inspirational product, hires local artisans, donates 10 percent of sales to charity and sells 20 percent stake to billionaire Jeff Bezos.” For […]
The Truth about Competition
October 11, 2012 by Leave a Comment
By Robert Cantrell In our IP strategy courses we teach about 10 different types of competitors. Depending upon the situation of an enterprise, some types of competitors will be more important than others. In some cases, the primary concern may be direct competitors. In others it may be a potential substitute or upstream competitors on […]
Life sciences IP management in an age of opportunity
October 10, 2012 by Leave a Comment
By Peter A Ackerman and Russell L Parr The life sciences industries provide some of the best examples of the risk/reward continuum inherent in the creation and commercialisation of ideas. The risks are considerable given the costs of complex research and development, regulatory requirement, and intellectual property owned by others that must be manoeuvred in order […]
Getting the most from your IP agent networks
October 9, 2012 by 1 Comment
By Donal O’Connell IP agent networks stretch around the globe and through every industry sector. Donal O’Connell and Sabine Baum outline best practice for managing those networks and turning them into crucial business assets One of the most essential elements in supporting a global intellectual property (IP) portfolio is the network of IP agents and […]
IP Strategy for Startups
October 8, 2012 by Leave a Comment
By Ian Maxwell Here are two very true statements A startup should have a patent portfolio Startups can rarely afford to properly invest in a patent portfolio With this fundamental paradox in mind, this article describes some of the options that startups have with respect to IP strategies that most effectively balance the costs and […]
ipstrategy.com 